|
PDMR
|
Ordinary Shares granted under the AZDBP
|
Ordinary Shares granted under the AZPSP
|
Award price per Ordinary Share
|
|
Pascal Soriot
|
8,734
|
87,346
|
£73.76
|
|
Marc Dunoyer
|
4,323
|
41,501
|
£73.76
|
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||
|
a)
|
Name
|
Pascal Soriot
|
|
|
2
|
Reason for the notification
|
||
|
a)
|
Position/status
|
Chief Executive Officer
|
|
|
b)
|
Initial notification /Amendment
|
Initial notification
|
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
AstraZeneca PLC
|
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
|
b)
|
Nature of the transaction
|
Grants of share awards under the AstraZeneca Performance Share Plan
and the AstraZeneca Deferred Bonus Plan
|
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
£73.76
|
96,080
|
||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
|
e)
|
Date of the transaction
|
6 March 2020
|
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||
|
a)
|
Name
|
Marc Dunoyer
|
|
|
2
|
Reason for the notification
|
||
|
a)
|
Position/status
|
Chief Financial Officer
|
|
|
b)
|
Initial notification /Amendment
|
Initial notification
|
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
AstraZeneca PLC
|
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
|
b)
|
Nature of the transaction
|
Grants of share awards under the AstraZeneca Performance Share Plan
and the AstraZeneca Deferred Bonus Plan
|
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
£73.76
|
45,824
|
||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
|
e)
|
Date of the transaction
|
6 March 2020
|
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
|
Media Relations
|
|
|
|
Gonzalo
Viña
|
|
+44 203 749 5916
|
|
Rob
Skelding
|
Oncology
|
+44 203 749 5821
|
|
Rebecca
Einhorn
|
Oncology
|
+1 301 518 4122
|
|
Matt
Kent
|
BioPharmaceuticals
|
+44 203 749 5906
|
|
Angela
Fiorin
|
BioPharmaceuticals
|
+44 1223 344 690
|
|
Jennifer
Hursit
|
Other
|
+44 203 749 5762
|
|
Christina
Malmberg Hägerstrand
|
Sweden
|
+46 8 552 53 106
|
|
Michele
Meixell
|
US
|
+1 302 885 2677
|
|
Investor Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203 749 5712
|
|
Henry
Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Christer
Gruvris
|
BioPharmaceuticals
(Cardiovascular, Metabolism)
|
+44 203 749 5711
|
|
Nick
Stone
|
BioPharmaceuticals (Renal) Environmental, Social and
Governance
|
+44 203 749 5716
|
|
Josie
Afolabi
|
BioPharmaceuticals (Respiratory)
|
+44 203 749 5631
|
|
Tom
Waldron
|
Other medicines
|
+44 7385 033 717
|
|
Craig
Marks
|
Finance
Fixed income
|
+44 7881 615 764
|
|
Jennifer
Kretzmann
|
Corporate access
Retail investors
|
+44 203 749 5824
|
|
US
toll-free
|
|
+1 866 381 72 77
|
|
|
AstraZeneca
PLC
|
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|